Multiple myeloma research crusader Kathy Giusti to speak at HBS Class Day

The founder of the Multiple Myeloma Research Foundation will speak at Harvard Business School Class Day.

Kathy Giusti

Kathy Giusti, M.B.A. ’85, founder and CEO of the Multiple Myeloma Research Foundation (MMRF), will address this year's imminent graduates of Harvard Business School as Class Day speaker. She founded the MMRF in 1998 after being diagnosed with multiple myeloma. This spring, Time magazine named her one of the "100 most influential people" in the world. Multiple myeloma is a cancer of plasma cells—white blood cells that produce antibodies; it affects from one to four people per 100,000 and constitutes 1 percent of all cancers. Before starting MMRF, Giusti was an executive with pharmaceutical companies, and she has sought to encourage the development of drugs to treat the disease using a business model, rather than an academic model, of drug development. The MMRF is the world's top funder of myeloma research: it has raised more than $165 million to fund research.  

Related topics

You might also like

Harvard Revamps Controversial Public Health School Center

The health and human rights center had drawn attention for its Palestine-related program.

Five Questions with Michèle Duguay

Harvard scholar of music theory on how streaming services have changed the experience of music.

Harvard Faculty Discuss Tenure Denials

New data show a shift in when, in the process, rejections occur

Most popular

Zelia Nuttall

Brief life of a remarkable anthropologist (1857-1933)

Harvard Students, Alumna Named Rhodes and Marshall Scholars

Nine Rhodes and five Marshall scholars will study in the U.K. in 2026.

Explore More From Current Issue

Professor David Liu smiles while sitting at a desk with colorful lanterns and a figurine in the background.

This Harvard Scientist Is Changing the Future of Genetic Diseases

David Liu has pioneered breakthroughs in gene editing, creating new therapies that may lead to cures.

Illustration of tiny doctors working inside a large nose against a turquoise background.

A Flu Vaccine That Actually Works

Next-gen vaccines delivered directly to the site of infection are far more effective than existing shots.